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TAp63 prevents premature aging, suggesting a link
to genes that regulate longevity. Further character-
ization of TAp63/ mice revealed that these mice
develop obesity, insulin resistance, and glucose
intolerance similar to those seen in mice lacking
two key metabolic regulators, Silent information
regulator T1 (Sirt1) and AMPK. While the roles of
Sirt1 and AMPK in metabolism have been well
studied, their upstream regulators are not well under-
stood. We found that TAp63 is important in regu-
lating energy metabolism by accumulating in
response to metabolic stress and transcriptionally
activating Sirt1, AMPKa2, and LKB1, resulting in
increased fatty acid synthesis and decreased fatty
acid oxidation. Moreover, we found that TAp63
lowers blood glucose levels in response to metfor-
min. Restoration of Sirt1, AMPKa2, and LKB1 in
TAp63/ mice rescued some of the metabolic
defects of the TAp63/ mice. Our study defines
a role for TAp63 in metabolism and weight control.
INTRODUCTION
Obesity is a global health problem, and obesity-related diseases
such as diabetes and heart disease are a critical threat to human
longevity (Banks et al., 2008; Flegal et al., 2005). The sirtuin
family of genes is an important regulator of longevity in multiple
organisms from yeast to mice (Haigis and Guarente, 2006;
Kume et al., 2010; Lin et al., 2000; Rogina and Helfand, 2004).
Sirt1 is one of seven sirtuin members in mammals and has
received a flurry of attention based on its ability to regulate
synthesis, storage, and utilization of lipids (Rodgers and Puig-
server, 2007; Takemori et al., 2011). Transgenic and knockout
mice of Sirt1 have phenotypes that have revealed critical clues
about its function in aging, metabolism, and cancer. For ex-
ample, Sirt1 transgenic mice are protected from glucose intoler-
ance and have a more active metabolism and leaner bodiesCell(Banks et al., 2008). Tissue-specific deletion in liver and brain
of Sirt1 in mice resulted in increased body weight, fatty liver,
and glucose intolerance associated with aging (Cohen et al.,
2009; Purushotham et al., 2009). Sirt1 also plays an important
role in cancer and has been shown to regulate genes involved
in senescence, DNA repair, and tumor suppression (Wang
et al., 2008).
Recent reports have indicated an interdependence of AMP-
activated protein kinase (AMPK) and Sirt1 (Canto´ et al., 2010)
in response to fasting and exercise. AMPK regulates energy
homeostasis through its ability to balance catabolic and anabolic
activity to regulate lipid and glucose metabolism (Hardie and
Frenguelli, 2007; Towler and Hardie, 2007). This function of
AMPK is critical for its response to metabolic stress. Importantly,
AMPK activation is required for the therapeutic benefits of the
drug metformin in the management of type 2 diabetes (Shaw
et al., 2004, 2005). The activation of AMPK occurs through
phosphorylation by the tumor suppressor and upstream kinase,
LKB1 (Woods et al., 2003).
Sirt1, AMPK, and LKB1 are key metabolic regulators. Sirt1
mediates metabolic and the physical beneficial effects of caloric
restriction (CR), such as the extension of life span, while AMPK
stimulates fatty acid oxidation (Boily et al., 2008; Canto´ et al.,
2010), and LKB1 is a regulator of AMPK. The mechanistic regu-
lation of these functions of Sirt1 and AMPK is primarily through
their ability to posttranslationally modify transcription factors,
such as FOXO1, p53, and acetyl-CoA carboxylase (ACC1),
thereby affecting their downstream functions (Banks et al.,
2008; Canto´ et al., 2009; Rodgers et al., 2005; Vaziri et al.,
2001). Sirt1 directly deacetylates p53 and AMPK phosphorylates
ACC1. The phosphorylation of ACC1 is critical for the production
of malonyl-CoA as a substrate for fatty acid biosynthesis. While it
is clear that Sirt1, AMPK, and LKB1 play crucial roles in energy
metabolism in response to different energy stresses, how they
are regulated in response to metabolic stress remains unclear.
Recently, we demonstrated that the p53 family member and
p63 isoform, TAp63, plays critical roles in aging and in the sup-
pression of tumorigenesis and metastasis (Flores et al., 2005;
Su et al., 2009, 2010). The vast majority of research on p63 has
been performed using mouse models deficient for all isoforms
of p63 (Mills et al., 1999; Yang et al., 1999). Using these mouse
models, p63 has been found to be critical for epidermalMetabolism 16, 511–525, October 3, 2012 ª2012 Elsevier Inc. 511
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tion of isoform-specific knockout mice for p53 family members
has unveiled unique functions for these genes (Guo et al., 2009;
Su et al., 2009, 2010; Suh et al., 2006). We have generated
TAp63/miceandhave found thatTAp63/miceageprema-
turely, andTAp63 is critical for themaintenanceof adult stemcells
in quiescence (Su et al., 2009). Loss of TAp63 triggers a senes-
cence program in TAp63-deficient tissues, resulting in premature
aging and reduced life span in mice (Guo et al., 2009; Su et al.,
2009). We also found that TAp63+/ and TAp63/ are highly
tumor prone and develop metastatic disease (Su et al., 2010).
Here, we show that in addition to these phenotypes, aging
TAp63/ mice develop multiple phenotypes consistent with
type 2 diabetes, including glucose intolerance, insulin resistance,
and liver steatosis (fatty liver). These mice phenocopy those
with tissue-specific deletions of Sirt1 as well as those deficient
for AMPKa (Cohen et al., 2009; Purushotham et al., 2009; Viollet
et al., 2003). Moreover, we found that TAp63 upregulates Sirt1
after calorie restriction. We found that the mechanism for these
phenotypes is the requirement for TAp63-mediated transcrip-
tional activation of Sirt1, AMPKa2, and LKB1. Consistent with
regulation of AMPKa2 and LKB1 by TAp63, we found that
TAp63 is critical for lowering blood glucose levels in response
to metformin, a drug used to treat type 2 diabetes. These find-
ings reveal roles for TAp63 in metabolism and indicate that
TAp63 is a potential therapeutic target for metabolic disorders.
RESULTS
TAp63–/– Mice Develop Obesity
Weobserved that as TAp63/mice age they become obese by
8 months of age (Figure 1A). By 12 months of age, we observed
that somemiceweighed asmuch as 91 g andwere immobile and
unable to access food and water (Figure 1B). We found that
TAp63/mice had increased body fat that was present under-
neath the skin and intercalated into multiple organs (Figure 1C).
To understand the role of TAp63 in obesity, we aged a cohort of
15 mice for 18 months and found that by 8 months of age, the
TAp63/ mice weighed 30% more than their wild-type (WT)
littermates (Figure 1D). This difference increased to 40% by
12 months of age (Figure 1D).
To systematically assess weight gain in the TAp63/ mice,
we maintained 15 TAp63/ and 15 WT mice on a high-fat (HF)
diet for 16 weeks beginning at 4 weeks of age. A similar number
of WT and TAp63/ mice were fed a control (con) or CR diet.
We found that as early as 2 weeks after being shifted to a HF
diet, the TAp63/ mice exhibited significant weight gain as
compared to WT mice (Figure 1E). TAp63/ mice fed control
or CR diets had body weights that were comparable to their WT
counterparts throughout the experiment (Figure 1E), indicating
that TAp63 is critical for regulating weight when mice are
challenged with HF diets. This was not due to increased food
intake, since we found no significant difference in the amount of
food consumed by TAp63/ mice compared to WT mice on
all three diets (Figures 1F and 1G and data not shown).
To determine whether the weight gain in the TAp63/ mice
could be attributed to differences in activity, we compared the
horizontal activity of five WT and five TAp63/ mice over
a 24 hr period and found the activity of the TAp63/ mice is512 Cell Metabolism 16, 511–525, October 3, 2012 ª2012 Elsevier Insignificantly lower than their WT littermates (Figure 1H). We
also measured levels of oxygen consumed and carbon dioxide
produced and found that TAp63/mice consume less oxygen
(Figure 1I) and produce less carbon dioxide (Figure 1J) than their
WT littermates. Moreover, we found that the respiratory quotient
(RQ) is higher in TAp63/ mice during the light cycle relative
to WT mice, indicating a relative resistance to fatty acid metab-
olism (Figure 1K). Lastly, we found that heat production in
TAp63/mice is significantly lower than inWTmice (Figure 1L).
Taken together, these data indicate that TAp63/ mice have
impaired energy metabolism.
TAp63 Regulates Energy Metabolism
To determine whether TAp63/ mice had defects in energy
metabolism, we measured glucose tolerance and serum levels
of triglycerides, cholesterol, and insulin. To determine whether
TAp63/ mice have decreased glucose tolerance, we chal-
lenged ten TAp63/ and ten WT mice at 12 months of age
with 2 g of glucose per kilogram of body weight. We found that
TAp63/mice had a significantly decreased glucose tolerance
as compared to WT mice (Figures 2A and 2B). To determine
whether this was an age-associated phenomenon, we chal-
lenged 15 TAp63/mice with a HF diet for 16 weeks beginning
at 4 weeks of age and measured the glucose tolerance of these
mice after 16 weeks on the HF diet (Figures 2C and 2D). We
found that young TAp63/ mice on a HF diet also developed
glucose intolerance (Figures 2C and 2D). Diabetes and insulin
resistance are associated with defects in glucose uptake.
To understand whether TAp63-deficient mice are defective
in glucose uptake, we measured the ability of TAp63/
mouse embryo fibroblasts (MEFs) to uptake glucose. Indeed,
TAp63/ MEFs had a dramatically reduced ability to uptake
glucose (Figure 2E). Glucose intolerance and defects in glucose
uptake are associated with insulin resistance and type 2
diabetes. To determine whether TAp63/mice develop insulin
resistance, we measured levels of glucose in WT and TAp63/
mice subsequent to insulin injection (Figure 2F) and found that
TAp63/ mice had significantly higher levels of glucose (Fig-
ure 2G), indicating resistance to insulin. We also found that
TAp63/ mice fed a control or a HF diet have significantly
higher serum insulin compared with their WT littermates at
5 months of age (Figure 2H). We have shown previously that
TAp63/mice exhibit signs of premature aging in some tissues
(Su et al., 2009, 2010). To determine whether the metabolic
defects observed in the TAp63/ mice are due to premature
senescence, we assayed for markers of senescence in MEFs
and livers of TAp63/ mice. We found that TAp63/ MEFs
at passage 2 had increased levels of senescence associated
b-galactosidase (Figure S1A). Therefore, we used passage 1
MEFs in all of our studies. Moreover, we found that livers from
TAp63/ mice did not show evidence of senescence and
expressed WT levels of p16Ink4a, p19Arf, and PML, indicating
that premature senescence was not the cause of the metabolic
defects of the TAp63/ mice (Figure S1B). Taken together,
these data are consistent with type 2 diabetes and other mouse
models with this disease (Memon et al., 1994).
Lipid accumulation and increased plasma levels of triglycer-
ides are associated with insulin resistance and type 2 diabetes
(Ginsberg et al., 2005). TAp63/ mice fed a control diet arec.
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Figure 1. TAp63–/– Mice Develop Obesity
(A) Photograph of 8-month-old WT (WT) and TAp63/ littermates.
(B) Twelve-month-old TAp63/ mouse (91 g).
(C) Representative examples of fat distribution in 8-month-old WT and TAp63/ mice.
(D) Body weight distribution of WT and TAp63/ mice at 8 and 12 months.
(E) Weekly weight of WT and TAp63/ mice fed with control or high-fat food (n = 15 per group).
(F and G) Food intake of WT and TAp63/ mice fed a control diet (F) or high-fat (HF) diet (G) from 1 to 5 months of age.
(H) Horizontal activity over a 24 hr period. n = 5 for each indicated genotype.
(I–L) Indirect calorimetry of WT (blue line) and TAp63/ (red line) mice: oxygen consumption (VO2) (I), carbon dioxide release (VCO2) per kg of lean body weight
(J), respiratory exchange ratio (RER, VCO2/CO2) (K), or energy expenditure kcal/hour (L). n = 5 mice. Data are represented as mean ± SEM. Asterisks indicate
statistical significance, p < 0.05.
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Figure 2. TAp63–/– Mice Are Glucose Intolerant and Insulin Resistant
(A) Glucose tolerance test performed on 12-month-old WT and TAp63/mice fasted for 18 hr (n = 10). Each point on the graph indicates the level of glucose in
the blood at the indicated time point on the x axis.
(B) Areas under the curves (AUC) calculated from mice in (A). n = 10 for each genotype.
(C) Glucose tolerance test performed on 5-month-old WT and TAp63/ mice fed a high-fat (HF) diet for 16 weeks (n = 15).
(D) AUC calculated from mice in (C). n = 15 for each genotype.
(E) Glucose uptake of WT and TAp63/ MEFs.
(F) Insulin tolerance test performed on 5-month-old WT and TAp63/ mice with control diet (n = 8).
(G) Areas under the curves (AUC) calculated from mice in (F) (n = 8).
(H) Serum insulin levels in WT and TAp63/ mice at 5 months of age after being fed a HF diet for 16 weeks.
(I) Blood serum levels of leptin in WT and TAp63/ mice at 5 months of age fed the indicated diet (n = 8).
(J) Serum triglyceride and cholesterol in WT and TAp63/ mice at 5 months of age after being fed a control (con) diet for 16 weeks.
(K) Blood serum levels of adiponectin inWT and TAp63/mice at 5 months of age fed the indicated diet (n = 8). Data are represented as mean ± SEM. Asterisks
indicate statistical significance, p < 0.05.
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the levels of lipids in these mice. Blood was drawn from 15
fasting TAp63/ and WT mice at 5 months of age that had
been maintained on a control diet. We found that the levels of
cholesterol, triglycerides, adiponectin, and leptin were signifi-
cantly higher in TAp63/ than in WT mice (Figures 2I–2K).
These data indicate that TAp63 is important for lipid metabolism
and that loss of TAp63 leads to obesity and diabetes in mice.
TAp63–/– Mice Develop Liver Steatosis
High levels of lipids and triglycerides in the blood are associated
with fat accumulation in the liver and liver steatosis (fatty liver
disease). To determine whether TAp63/ mice develop liver
steatosis, we examined hematoxylin and eosin (H&E)-stained
livers from TAp63/ and WT mice (Figures 3A–3H). We found
that livers from 12-month-old TAp63/ mice fed control
chow had many areas of fat deposition as compared to livers
from WT mice of the same age (Figures 3A and 3E). Even livers
from young TAp63/ mice at 5 months of age that were fed
control, CR, and HF diets for 16 weeks beginning at 4 weeks
of age exhibited a higher accumulation of fat than their WT coun-
terparts (compare Figures 3B and 3F, Figures 3C and 3G, and
Figures 3D and 3H). This was further demonstrated by oil
red O staining showing accumulation of lipids in the livers of
TAp63/ mice (compare Figures 3I and 3M, Figures 3J and
3N, Figures 3K and 3O, and Figures 3L and 3P). These data indi-
cate that lipids accumulate in the tissues of TAp63/ mice.
Increased lipid deposition in the blood, liver, and other tissues
can be caused by increased fatty acid synthesis, decreased utili-
zation of lipids, or both. To determine whether levels of important
regulators of lipid homeostasis were affected in the absence
of TAp63, we measured mRNA levels derived from livers of
5-month-old TAp63-deficient mice fed a control diet for fatty
acid synthase (FAS), an enzyme that catalyzes fatty acid
synthesis, leading to increased incorporation of free fatty acids
into triglycerides (Figure 3Q), and carnitine palmitoyltransfer-
ase-1 (CPT-1) (Figure 3R), a rate-limiting enzyme for fatty acid
oxidation. We found that the mRNA levels were altered in livers
from TAp63/ mice compared to WT mice, suggesting that
the increase in the levels of lipids in TAp63-deficient mice is
due to deregulation of these metabolic enzymes. Moreover, we
examined a panel of genes involved in lipid storage and metab-
olism and found that expression of these mRNAs is deregulated
in the absence of TAp63 (Figure 3S).
To determine the contribution of CPT-1 deregulation to lipid
metabolism and mitochondrial dysfunction in TAp63-deficient
mice, we measured the oxygen consumption rate in control
and TAp63/ MEFs under basal conditions and in response
to palmitate, the substrate of CPT-1. TAp63/MEFs exhibited
low basal mitochondrial oxygen consumption (Figure 3T) and
an impaired ability to metabolize palmitate (Figure 3U). These
data indicate that TAp63/ mice have defects in both fatty
acid accumulation and fatty acid oxidation. On the basis of these
findings, we conclude that fatty acid synthesis is increased and
fatty oxidation is decreased in TAp63/ mice.
TAp63 Regulates the Sirt1/AMPK/LKB1 Pathway
The altered expression of enzymes regulated by silent informa-
tion regulator T1 (Sirt1) and/or AMPKa in TAp63-deficient miceCell(Figures 3Q–3S) led us to ask whether TAp63 regulates lipid
metabolism through Sirt1, AMPK, or LKB1. We measured the
protein and mRNA levels of these energy sensors and metabo-
lism regulators in tissues from TAp63-deficient mice at 4 weeks
and 5 months of age. We found that MEFs (Figure 4A) and
muscle from 4-week-old TAp63/ mice have lower levels of
Sirt1 than their WT counterparts, while liver fat and skin showed
no significant difference (Figure 4B). Importantly, we found that
levels of Sirt1 are unchanged in the skin of TAp63/mice (Fig-
ure 4B), suggesting that TAp63 regulates Sirt1 expression in
metabolic tissues. In contrast, by 5 months of age, we could
see that Sirt1 is lower in muscle, fat, and liver. This difference
could also be seen in tissues from TAp63/mice fed a control
(con) or CR diet (Figures 4C–4E). When TAp63/ mice were
fed a HF diet, Sirt1 levels were only found to be lower in fat
(Figures 4C–4E).
Levels of Sirt1 are upregulated in response to CR through
a mechanism that is not clearly understood, and levels of Sirt1
decline with age (Brooks and Gu, 2009). To determine whether
TAp63 is required for Sirt1 upregulation in response to CR, we
measured the levels of Sirt1 in the livers of 5-month-old WT
and TAp63/ mice that had been on a CR diet for 16 weeks
beginning at 4 weeks of age. At this age, levels of Sirt1 were
lower in muscle and fat of TAp63/ mice compared to WT
mice (Figures 4C–4E). These data indicate a role for TAp63 in
Sirt1 upregulation in response to CR in certain tissues, like
muscle and fat. Sirt1 is known to deacetylate p53. To ask
whether p53 is deacetylated by Sirt1 in the absence of TAp63
where levels of Sirt1 are low, we performed western blot analysis
for acetylated p53 in the muscle, fat, and livers of TAp63/
mice fed a con, CR, or HF diet. We found that in all cases there
is an increase in p53 acetylation (Figure 4C), indicating that Sirt1
in not functional in the absence of TAp63.
To determine if the difference occurred at the transcriptional
level, we assayed the levels of Sirt1mRNA in WT and TAp63/
MEFs starved for 6 hr. We found that while levels of Sirt1 are up-
regulated in WT MEFs, the levels of Sirt1 remain unchanged in
TAp63/MEFs, suggesting that TAp63 is required for upregu-
lation of Sirt1 in response to glucose starvation (Figure 4F).
Moreover, we found that Sirt1 levels are upregulated in WT
mice that were fasted for 18 hr, while levels of Sirt1 do not
change after this treatment in livers isolated from TAp63/
mice (Figure 4G). These data indicate that TAp63 is necessary
for the transcriptional upregulation of Sirt1 in the CR response.
AMPK is another critical regulator of lipid and glucose metab-
olism. Activation of AMPK results in an increase in ATP produc-
tion by increasing fatty acid oxidation and glucose uptake.
Dysfunction of hepatic AMPK induces lipid accumulation and
hyperlipidemia, which is associated with diabetes (Zang et al.,
2006). Given the importance of the LKB1/AMPK in the regulation
of fat oxidation and gluconeogenesis and the accumulation of
lipids in the tissues from TAp63/ mice, we examined the
protein levels of AMPKa and LKB1 in livers from WT and
TAp63/ mice. We found that in 4-week-old TAp63/ mice
expression of AMPKa is significantly lower in muscle and fat
compared to WT littermates (Figure 4H). Expression of LKB1 is
lower only in the muscle of TAp63/ mice at 4 weeks of age
(Figure 4H). To determine whether this was an age-associated
phenomenon, we assessed AMPKa and LKB1 expression inMetabolism 16, 511–525, October 3, 2012 ª2012 Elsevier Inc. 515
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Figure 3. TAp63–/– Mice Display Defects in Fatty Acid Oxidation
(A–H) Hematoxylin and eosin-stained cross-sections of livers fromWT (A–D) and TAp63/ (E–H) mice at 12months of age (A and E) and at 5months of age after
being fed a control (con) (B and F), calorie-restricted (CR) (C and G), or high-fat (HF) (D and H) diet for 16 weeks. Arrows indicate areas of lipid deposits.
(I–P) Oil red O staining of liver from samples shown in (A–H). Red staining indicates lipid deposits.
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TAp63 Regulates Lipid and Glucose Metabolism5-month-old WT and TAp63/ mice fed control, CR, or HF
diets. We found that AMPKa is low in muscle, fat, and liver of
TAp63/ mice fed a control or CR diet (Figures 4I–4K). Five-
month-old TAp63/ mice fed a HF diet expressed low levels
of AMPKa in fat and liver only and not in muscle (Figures
4I–4K). We found that LKB1 expression is lower in muscle, fat,
and liver of 5-month-old TAp63/ mice fed a control diet
(Figures 4I–4K). When these mice were fed a CR or HF diet,
significant differences in LKB1 expression were detected in fat
and liver only and not in muscle (Figures 4I–4K). Taken together,
these data indicate that TAp63 regulates expression of AMPKa
and LKB1 in a tissue- and context-specific manner and seems
to play a more significant role in fat and liver.
We next asked whether levels of the catalytic subunits of
AMPK, AMPKa1 and AMPKa2, were decreased in TAp63/
mice (Figures 4L and 4M). We found that the level of AMPKa2
was significantly lower in young TAp63/ mice fed a control
or HF diet (Figure 4L). These data suggest that AMPKa2 is the
subunit that is transcriptionally regulated by TAp63 in the liver.
To determine whether metabolic defects led to defects in the
development of metabolic tissues in TAp63/ mice, we per-
formed histological analysis and electron microscopy of cross-
sections of fat and muscle (Figure S2). We found no significant
differences between these tissues in WT and TAp63/ mice
(Figure S2).
TAp63 Is Critical for the Response to Metformin
Previous studies have shown that AMPKa is phosphorylated
and activated by the tumor suppressor and upstream kinase,
LKB1, in response to metformin (Shaw et al., 2004, 2005; Woods
et al., 2003). To determine whether TAp63 is required for the
response to metformin and whether AMPKa is phosphorylated
in the absence of TAp63, we tested the activation of AMPKa
and TAp63 in livers from 5-month-old WT and TAp63/ mice
treated with metformin. We have previously shown that
TAp63g can be activated and accumulates in response to
multiple stresses, including DNA damage and wound healing
(Su et al., 2009). Importantly, we found that TAp63g accumu-
lates in response to metformin in livers of WT mice at 5 months
of age (Figure 5A). Additionally, we found that LKB1 is upregu-
lated with a concomitant phosphorylation of AMPKa in WT livers
as reported previously (Canto´ et al., 2010; Shaw et al., 2004,
2005; Woods et al., 2003), while no such regulation occurred
in the absence of TAp63 (Figure 5A). We also measured phos-
phorylation of a downstream target of AMPK, acetyl-CoA
carboxylase, ACC1, and found that levels of phosphorylated
ACC1 are significantly lower in livers of TAp63/ mice (Fig-
ure 5B), indicating that AMPKa is functionally inactive in the
absence of TAp63. To further investigate the kinetics of the
regulation of the LKB1-AMPK pathway by TAp63, we measured
protein expression of TAp63, LKB1, and phosphorylated(Q) Quantitative real-time PCR (qRT-PCR) analysis of FAS from total RNA isolate
(R) qRT-PCR analysis of CPT-1 from mRNA isolated from livers of WT and TAp6
(S) qRT-PCR analysis of lipid synthesis, oxidation, and gluconeogenesis pathway
after fasting for 18 hr (n = 3).
(T) Linear graph showing basal oxygen consumption rate (OCR) in WT and TAp6
(U) Oxygen consumption rate (OCR) in WT and TAp63/ MEFs in response to
mean ± SEM. Asterisks indicate statistical significance, p < 0.05. Double asteris
CellAMPKa in AML-12 hepatocytes after treatment with metformin
for 30 min, 2 hr, 6 hr, and 24 hr. We found that TAp63g accumu-
lates 30 min after treatment with metformin with a concomitant
phosphorylation of AMPKa (Figure 5C). Importantly, we also
found that levels of TAp63g accumulate in vivo, in mouse livers,
1 hr after metformin treatment, with peak expression at 2 hr.
High expression of TAp63g correlated with peak expression of
LKB1 and phosphorylation of AMPKa in WT mice (Figure 5D).
We did note that in 5-month-old TAp63/ mice there was
not a significant increase in LKB1 (Figure 5A), while in young
4-week-old TAp63/ mice there was still an increase in
LKB1 (Figure 5D), indicating an age-related factor in TAp63’s
ability to regulate LKB1 in response to metformin. These data
indicate that TAp63 is required for LKB1 activation and down-
stream phosphorylation of AMPKa in response to metformin in
older mice.
Because TAp63 deficiency leads to a blunted activation of
the LKB1-AMPK pathway, we next asked whether metformin
could lower blood glucose levels in TAp63/ mice. We
treated eight WT and TAp63/ mice at 4 weeks of age with
250 mg/kg body weight of metformin. We found significantly
higher levels of glucose in the blood of TAp63/ mice com-
pared to WT mice (Figure 5E), indicating a poor response to
metformin in the absence of TAp63. Taken together, these
data indicate that TAp63g responds to metformin and is critical
for the downstream responses that regulate glucose levels and
utilization.
TAp63 Transcriptionally Activates Sirt1, AMPKa2,
and LKB1
We observed low levels of Sirt1, AMPKa, and LKB1 in the
absence of TAp63, suggesting that they may be transcriptionally
regulated by TAp63. To determine if this is the case, we per-
formed chromatin immunoprecipitation (ChIP) and Luciferase
reporter gene assays. We identified a putative p63 response
element within the Sirt1 promoter located 2,016 nucleotides
upstream of the start site (Table S1). Indeed, in a ChIP assay,
we found that TAp63 binds to this response element, but not
a nonspecific binding site located 2,000 nucleotides upstream
of the p63 binding site (Figure 6A). We next performed a Lucif-
erase reporter gene assay and found that the TAp63b and g
isoforms can activate the Sirt1-luciferase reporter gene 4–5
times over vector alone (Figures 6B and 6C). p53 and TAp63a
were unable to activate this reporter gene (Figure 6C). To
confirm the specificity of the identified p63 binding site on the
Sirt1 promoter, we generated a Sirt1-luciferase reporter gene
with a mutated p63 binding site (Figure 6B). The p63 isoforms
were unable to activate this reporter gene and an additional
luciferase reporter gene with a nonspecific p63 binding site
(Figures 6B and 6C). These data indicate that TAp63 binds to
the Sirt1 promoter and can transcriptionally activate it and thatd from livers of WT and TAp63/ mice, n = 3.
3/ mice fed a con or HF diet for 16 weeks (n = 3).
genes from mRNA isolated from livers of control diet WT and TAp63/mice
3/ MEFs.
palmitate. Arrow indicates addition of palmitate (PA). Data are represented as
ks indicate significant difference between WT con and WT HF groups in (R).
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Figure 4. Sirt1, AMPK, and LKB1 Expression in TAp63-Deficient Mice
(A–E)Western blot for Sirt1 using lysates extracted from:WT and TAp63/MEFs (A); liver, muscle, fat, and skin frommice at 4weeks of age fed a control diet (B);
or the indicated tissues from 5-month-old mice fed a control (con), calorie-restricted (CR), or high-fat (HF) diet for 16 weeks (C–E).
(F and G) qRT-PCR for Sirt1 using RNA extracted from: glucose-starvedMEFs (F) or livers ofWT and TAp63/mice before (con) and 18 hr after fasting (fast) (G).
(H–K) Western blot for AMPKa using lysates from the indicated WT and TAp63/ tissues extracted from mice at 4 weeks of age (H) or from lysates extracted
from the indicated tissues of mice at 5 months of age fed a control (con), calorie-restricted (CR), or high-fat (HF) diet for 16 weeks (I–K).
(L andM) qRT-PCR for AMPKa2 (L) and AMPKa1 (M) in livers of WT and TAp63/mice at 5months of age after being fed a con or HF diet for 16weeks. Data are
represented as mean ± SEM. Asterisks indicate statistical significance, p < 0.05.
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response.
Importantly, we also found that AMPKa2 mRNA and protein
levels are significantly lower in metabolic tissues from518 Cell Metabolism 16, 511–525, October 3, 2012 ª2012 Elsevier InTAp63/ mice compared to their WT counterparts (Figures
4H–4M). To determine whether TAp63 is a transcriptional regu-
lator of AMPKa2, we performed ChIP and luciferase analyses.
We identified a TAp63 binding site 1,235 nucleotides upstreamc.
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Figure 5. TAp63 Is Required for the
Response to Metformin
(A and B) Western blot analysis of lysates from
livers of WT and TAp63/ mice at 5 months of
age before (UN) and after metformin (metf) injec-
tion using the indicated antibodies.
(C and D) Western blot analysis of lysates from
AML-12 cells (C) or livers from WT (+/+) and
TAp63/ (/) mice at 4 weeks of age (D) after
treatment with metformin at the indicated time
points using the indicated antibodies. Numbers
above each western blot were measured and
quantified by densitometry.
(E) Blood glucose levels in WT and TAp63/
mice after metformin injection. Measurements
were plotted at 30 min intervals for 2 hr, n = 8. Data
are represented as mean ± SEM. Asterisks indi-
cate statistical significance, p < 0.05.
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TAp63 Regulates Lipid and Glucose Metabolismof the start site (Table S1). Interestingly, we could only detect
binding of TAp63 at the AMPKa2 promoter in cells treated with
1 mM metformin, an activator of AMPK and a drug used to treat
type 2 diabetes, suggesting that TAp63 may activate the AMPK
pathway in response to metformin. We also found that TAp63b
and g isoforms can activate an AMPKa2-luciferase reporter
gene containing the identified binding site (Figures 6D–6F).
AMPKa2-luciferase reporter gene with mutations in the p63
binding site or a nonspecific binding site resulted in a complete
abrogation of transactivation (Figures 6E and 6F). These data
indicate that TAp63 is a transcriptional activator of AMPKa2
and that this regulation may be critical for the regulation of
energy metabolism.
LKB1 protein expression was also found to be significantly
lower in TAp63/mice (Figures 4H–4K). To determine whether
TAp63 is a transcriptional regulator of LKB1, we again performed
ChIP (Figure 6G) and luciferase analyses (Figures 6H and 6I) and
found a TAp63 binding site within intron 1 of LKB1 (Table S1).
This site was activated by TAp63a and TAp63b in luciferase
reporter assays (Figure 6I). Taken together, these data indicate
that TAp63 can bind to the Sirt1, AMPKa2, and LKB1 promoters
and can transcriptionally activate them.Cell Metabolism 16, 511–525We also examined the ability for TAp63
to bind to the Sirt1, AMPKa2, and LKB1
promoters in hepatocytes (AML-12 cells)
where we found that levels of TAp63 are
upregulated in response to metformin
(Figure 6J) or glucose starvation (Fig-
ure 6K). In AML-12 cells, we found that
TAp63g is upregulated in response to
metformin (Figure 6J), resulting in binding
to the Sirt1 (Figure 6L), AMPKa2 (Fig-
ure 6M), and LKB1 promoters (Figure 6N).
Additionally, we found that TAp63g is
upregulated in AML-12 hepatocytes in
response to glucose starvation (Fig-
ure 6K), resulting in binding to the Sirt1
(Figure 6O), AMPKa2 (Figure 6P), and
LKB1 promoters (Figure 6Q). These data
indicate that metabolic stress such asstarvation or addition of metformin results in upregulation of
TAp63g and downstream transcriptional regulation of these
key metabolic regulators.
TAp63 Upregulates Sirt1 in Response to Calorie
Restriction
We have shown that TAp63 transcriptionally activates Sirt1
(Figures 6A–6C, 6L, and 6O). Sirt1 is an important regulator in
the response to CR by regulating the expression of PEPCK
and GLS2 (a gene that encodes a mitochondrial glutaminase
catalyzing the hydrolysis of glutamine to glutamate), two critical
enzymes for mice to adapt to CR. Given the low levels of Sirt1 in
tissues from TAp63-deficientmice, we tested the CR response in
TAp63/mice. To do this, we fed 15 TAp63/ and WT mice
a CR diet beginning at 4 weeks of age. After 16 weeks of being
fed a CR diet, we measured fasting levels of triglycerides and
glucose in blood from these mice (Figures S3A and S3B). Impor-
tantly, we found that triglycerides were elevated in TAp63/
mice (Figure S3A) and that glucose levels were lower in
TAp63/ mice than in WT mice (Figure S3B). These data are
consistent with our previous data indicating defects in fat utiliza-
tion, fatty acid oxidation, and glucose utilization in the TAp63/, October 3, 2012 ª2012 Elsevier Inc. 519
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Figure 6. TAp63 Transcriptionally Activates Sirt1, AMPKa2, and LKB1
(A) qRT-PCR of ChIP assay using WT and TAp63/ keratinocytes showing the percentage of TAp63 bound to the Sirt1 promoter.
(B) Schematic showing TAp63 binding site (TAp63BS) on the Sirt1 promoter and nonspecific binding site (NSBS) luciferase reporter gene. TAp63BS and amutant
of this site (TAp63BSM) are shown.
(C) Luciferase reporter gene assay for Sirt1 in p53/;p63/ MEFs transfected with the indicated p63 isoforms and luciferase reporter genes.
(D) qRT-PCR of ChIP assay using WT and TAp63/ keratinocytes showing the percentage of TAp63 bound to the AMPKa2 promoter.
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TAp63 Regulates Lipid and Glucose Metabolismmice (Figures 1–3). Taken together, these data demonstrate that
the metabolic phenotype of the TAp63/mice is similar to that
of the Sirt1/ mice and that TAp63 upregulates Sirt1 in
a tissue-specific manner in response to CR.
Expression of Sirt1, AMPK, and/or LKB1 Rescues
Metabolic Defects in TAp63–/– MEFs
To determine whether the metabolic defects observed in the
TAp63/ MEFs could be rescued, we transfected WT and
TAp63/ MEFs with vectors expressing Sirt1, AMPKa2,
LKB1, or Sirt1 and LKB1 in combination (Figure S3C). To ask
whether expression of these genes could rescue the defects in
the mitochondria of TAp63/ MEFs, we measured mitochon-
drial membrane potential using the JC-1 assay. We found that
expression of Sirt1 or AMPKa2 partially rescues the mitochon-
drial defect while expression of both Sirt1 and AMPKa2
completely rescue the mitochondrial defect of the TAp63/
MEFs (Figure S3D). We also asked whether the rate of basal
oxygen consumption in TAp63/ MEFs could be restored to
WT levels by expression of Sirt1, AMPKa2, or LKB1. Indeed,
we found that expression of Sirt1 in TAp63/ MEFs partially
rescues oxygen consumption of TAp63/MEFs while expres-
sion of AMPKa2 completely rescues the defect in the TAp63/
MEFs (Figure S3E). These data indicate that re-expression
of Sirt1, AMPKa2, or LKB1 can rescue the defects of the
TAp63/ MEFs and indicate that regulation of these genes
by TAp63 leads to the metabolic defects in TAp63-deficient
cells.
Expression of Sirt1, AMPK, and/or LKB1 Rescues
Metabolic Defects in TAp63–/– Mice at 4 Weeks of Age
To ask whether expression of Sirt1, AMPKa2, or LKB1 could
rescue the defects of the TAp63/ mice in vivo, we infected
TAp63-deficient mice at 4 weeks of age with adenoviruses
expressing these genes via tail vein injection (Figure 7). Expres-
sion of AMPKa2 in the livers of TAp63/ mice (Figure 7A)
resulted in a rescue of expression of CPT-1, a key regulator of
fatty acid metabolism (Figures 7B and 7C). We did not see signif-
icant rescue in respiration, glucose tolerance, or fatty liver
disease in the mice (Figure S4). This may be due to the age of
themice or that themethod of delivery of virus to the liver is insuf-
ficient to rescue all of the phenotypes, i.e., expression of
AMPKa2 needs to be expressed in muscle and fat or other
tissues in the TAp63/ mice to fully rescue the metabolic
defects. Expression of LKB1 rescued the expression of AMPKa
and phosphorylation of AMPKa in the livers of TAp63/ mice(E) Schematic showing TAp63 binding site (TAp63BS) on the AMPKa2 promote
a mutant of this site (TAp63BSM) are shown.
(F) Luciferase reporter gene assay for AMPKa2 in p53/;p63/ MEFs transfe
(G) qRT-PCR of ChIP assay using WT and TAp63/ keratinocytes showing the
(H) Schematic showing TAp63 binding site (TAp63BS) on the LKB1 promoter
a mutant of this site (TAp63BSM) are shown.
(I) Luciferase reporter gene assay for LKB1 in p53/;p63/ MEFs transfected
(J and K) Western blot analysis of lysates from AML-12 cells after treatment with
(L–N) qRT-PCR of ChIP assay using AML-12 cells treated with metformin showin
(M), and LKB1 promoter (N).
(O–Q) qRT-PCR of ChIP assay using AML-12 cells before and after starvation
promoter (P), and LKB1 promoter (Q). Data are represented as mean ± SEM. Aste
indicates mutated sites within the binding site.
Cell(Figure 7D). We also found that STRAD is expressed at low
levels in TAp63/ mice, one of the other components of the
LKB1-MO25-STRAD complex (Figure 7D), while no change
was seen in MO25. Importantly, TAp63/ mice expressing
LKB1 responded to metformin, similar to their WT counterparts
(Figure 7E). These data indicate that TAp63 regulates LKB1
and is critical for the response to metformin. Lastly, we found
that expression of Sirt1 in TAp63/ mice resulted in WT
expression of PEPCK and GLS2 in the liver (Figure 7C). Also,
the levels of triglycerides in the blood are restored to WT levels
in TAp63/mice expressing Sirt1 (Figure 7G). Taken together,
these data indicate that re-expression of Sirt1, AMPKa2,
or LKB1 can rescue some of the metabolic defects of the
TAp63/ mice at 4 weeks of age and indicate that regulation
of these genes by TAp63 is critical for lipid and glucose
metabolism.
DISCUSSION
The roles of tumor suppressor genes in metabolism are an area
of intense interest and research (Bensaad et al., 2006; Jones and
Thompson, 2009; Matoba et al., 2006). The altered mechanisms
used by cancer cells to circumvent limiting nutrients are key to
the survival and growth of a tumor. Here, we show that the tumor
suppressor gene and p53 family member, TAp63, plays critical
roles in regulating energy metabolism. We found that TAp63/
mice develop obesity, glucose intolerance, and insulin resis-
tance. The TAp63/ mice have defects in fatty acid oxidation
and display mitochondrial dysfunction. These phenotypes of
the TAp63/ mice are reminiscent of tissue-specific deletion
of Sirt1 and AMPKa2/ mouse models (Cohen et al., 2009;
Purushotham et al., 2009; Viollet et al., 2003). We found that
TAp63 transcriptionally activates Sirt1, AMPKa2, and LKB1.
Loss of expression of these factors leads to defects in lipid utili-
zation, fatty acid synthesis, fatty acid oxidation, and insulin resis-
tance. Consequently, the TAp63/ mice exhibit symptoms of
premature aging (Su et al., 2009), obesity, and type 2 diabetes.
Importantly, we were able to rescue some of the metabolic
defects of the TAp63/ mice by expressing Sirt1, AMPKa, or
LKB1 in the liver of TAp63/ mice at 4 weeks of age. These
data reveal a role for TAp63 in regulating energy metabolism
and identify TAp63 as master upstream regulator of lipid and
glucose metabolism. Given the extensive interaction between
the p53 family members, these data have important implications
for understanding how the family of p53 tumor suppressor genes
regulates metabolism in cancer cells.r and nonspecific binding site (NSBS) luciferase reporter gene. TAp63BS and
cted with the indicated p63 isoforms and luciferase reporter genes.
percentage of TAp63 bound to the LKB1 promoter.
and nonspecific binding site (NSBS) luciferase reporter gene. TAp63BS and
with the indicated p63 isoforms and luciferase reporter genes.
metformin (J) or starvation (K).
g the percentage of TAp63 bound to the Sirt1 promoter (L), AMPKa2 promoter
showing the percentage of TAp63 bound to the Sirt1 promoter (O), AMPKa2
risks indicate statistical significance, p < 0.05. Red text in panels (B, E, and H)
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Figure 7. Expression of AMPKa2, LKB1, and Sirt1 in MEFs and Liver Rescues the Metabolic Defects of TAp63–/– Mice
(A) Western blot analysis of liver lysates from TAp63/ mice with or without adenovirus-AMPKa2 (ad-AMPKa2) infection and using the indicated antibodies.
(B and C) Bar graph indicating qRT-PCR analysis of CPT-1 (B), FAS (C) from total RNA isolated from livers of WT and TAp63/ mice, and TAp63/ mice
expressing AMPKa2.
(D) Western blot analysis of liver lysates fromWT, TAp63/, and TAp63/mice expressing LKB1 and treated with metformin using the indicated antibodies.
(E) Blood glucose levels after metformin injection of WT, TAp63/, and TAp63/ mice expressing LKB1. Measurements were plotted at 30 min intervals
for 2 hr.
(F) Western blot analysis of liver lysates from WT, TAp63/, and TAp63/ mice expressing Sirt1 using the indicated antibodies.
(G) Serum triglyceride levels in WT, TAp63/, and TAp63/ mice expressing Sirt1. Actin was used as a loading control in western blot analyses. Data are
represented as mean ± SEM.
Cell Metabolism
TAp63 Regulates Lipid and Glucose MetabolismThe roles of p63 have been extensively studied in epidermal
morphogenesis (Mills et al., 1999; Yang et al., 1999), epidermal
homeostasis (Su et al., 2009), and tumor suppression (Flores
et al., 2005; Guo et al., 2009; Su et al., 2010). While the vast
majority of p63 studies have been performed using mice that
are deficient for all isoforms of p63 (Mills et al., 1999; Yang
et al., 1999), our TAp63 isoform-specific knockout mice have
unveiled functions for this isoform that have not been previously
appreciated in studies using the p63/ mice. Here we show
that TAp63 is a critical transcriptional regulator of genes involved522 Cell Metabolism 16, 511–525, October 3, 2012 ª2012 Elsevier Inin lipid and glucose metabolism. Given the extensive interaction
of the p53 family members (Flores et al., 2002, 2005; Lang et al.,
2004; Olive et al., 2004), our findings have important implications
for the p53 family in regulating metabolism in cancer. Previous
studies have shown that p53 plays critical roles in regulating
metabolism. The primary mechanism of action of p53 in this re-
gard is through transcriptional activation of downstream target
genes. These include TIGAR (TP53-induced glycolysis regu-
lator), SCO2 (synthesis of cytochrome c oxidase) (Bensaad
et al., 2006; Matoba et al., 2006), sestrin 1 and 2 (Budanov andc.
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TAp63 Regulates Lipid and Glucose MetabolismKarin, 2008), and AMPKb (Feng et al., 2007). Cells within a tumor
are nutrient deprived and use aerobic glycolysis as their major
source of energy, the so-called Warburg effect. The switch to
this mode of metabolism is critical for the survival of cells prolif-
erating in a tumor with limited blood and oxygen. Here, we found
that TAp63 transcriptionally regulates Sirt1, AMPKa2, and LKB1
to regulate the utilization of fat and glucose. This has important
implications for tumor cells with mutant p53. Mutant p53 has
been shown to bind to TAp63 and inhibit its transcriptional
activity (Gaiddon et al., 2001; Lang et al., 2004; Olive et al.,
2004). Mice lacking TAp63 are highly prone to metastatic tumors
(Su et al., 2010) and to metabolic disorders, as we have shown
here. The ability of mutant p53 to inactivate TAp63 suggests
there may be interplay between p53 family members in regu-
lating cellular metabolism in cancer. Therefore, our work has
opened venues of investigation for the p53/p63/p73 field.
Consistent with a role for TAp63 in metabolic stress, we found
that TAp63 responds to a drug used to treat type 2 diabetes,
metformin. The levels of TAp63g are elevated in response to
metformin (Figures 5A, 5C, and 5D). In turn, levels of LKB1
increase, which not only regulates energy metabolism through
its ability to phosphorylate AMPKa but is also a potent tumor
suppressor gene (Shaw et al., 2004, 2005; Woods et al., 2003).
Therefore, we found two modes by which TAp63 regulates
AMPKa. One is through regulating the mRNA levels of AMPKa2
itself and the other is by regulating its upstream kinase, LKB1.
The reasons for this multilevel regulation are intriguing and areas
for future research. Possible reasons for this complex regulation
could be due to different cellular and metabolic stress contexts.
We have shown here that TAp63 is a critical regulator of lipid
and glucose metabolism, loss of which leads to obesity and dia-
betes. Not only is TAp63 a potent suppressor of tumorigenesis
and metastasis (Su et al., 2010), it is also a central regulator
and integrator of the metabolic response to CR and starvation.
These findings provide exciting avenues of research for the
p53 family and cancer fields.
EXPERIMENTAL PROCEDURES
Mice and Diet Regimen
Forty-five TAp63/ and WT (WT) male mice on an enriched C57BL/6
background at 4 weeks of age were randomly assigned to three groups of
15 mice each. Each group was fed a control diet (con) (D12329, Research
Diets, New Brunswick, NJ; 11% kcal from fat), HF diet (HF) (D12492, Research
Diets; 60% kcal from fat), or calorie restricted diet (CR) (60% of the average
daily food intake of the control group) for 16 weeks. Each mouse was housed
individually. All procedures were approved by the IACUC at the University of
Texas M.D. Anderson Cancer Center.
Intraperitoneal Glucose and Insulin Tolerance Test
Intraperitoneal glucose tolerance test (IPGTT) was performed by injecting
D-glucose (2 g/kg body weight) intraperitoneally into mice that were fasted
for 18 hr. Insulin tolerance test (ITT) was performed by injecting mice intraper-
itoneally with insulin (0.75 U/kg, Humulin-N from Eli Lilly) in0.1ml 0.9%NaCl.
Blood was collected from tail bleeds every 20–30 min over a 2 hr period, and
whole-blood glucose wasmeasured using a Precision Xtra advanced diabetes
management system (MediSense). Areas under the curves for the IPGTT and
ITT were calculated using PRISM5 software (GraphPad).
Metabolite Measurements
Horizontal activity, oxygen consumption rate (VO2), carbon dioxide release
(VCO2), respiratory exchange ratio (RER), and heat production weremeasuredCellunder a consistent environmental temperature and light cycle using an indirect
calorimetry system (TSE Systems). After 3 days of acclimation to themetabolic
chamber, VO2 was measured in individual mice at 5 min intervals for 72 hr.
Data are normalized with respect to lean body weight. RER is the ratio of
VCO2 to VO2. Horizontal activity was measured on x, y, and z axes by using
infrared beams to count the beam breaks during a specified measurement
period. Fat and lean tissue mass was determined in living, nonanesthetized
mice by using a magnetic resonance imaging (MRI) at the Baylor College of
Medicine Metabolism Core.
Blood Serum Measurements
Mice were fasted for 18 hr prior to collecting blood. Serumwas analyzed using
a Insulin Mouse Ultrasensitive ELISA kit (cat# 80-INSMSU-E01, ALPCO),
Mouse Adiponectin ELISA kit (cat# CYT286, Chemicon), Mouse Leptin ELISA
Kit (Millipore Lactate Reagent Kit), and the COBAS INTEGRA 400 plus System
(Roche) to measure serum triglycerides and total cholesterol.
Oil Red O Staining
Frozen sections of livers from WT and TAp63/ mice were fixed with 10%
formalin. Oil red O (Polysciences, Inc.) staining was performed using 60%
isopropanol saturated with oil red O dye for 1 hr at room temperature.
Chromatin Immunoprecipitation Assay
Keratinocytes and AML-12 hepatocytes used to assess TAp63 binding at the
AMPKa2 promoter were treated with 1 mM metformin for 6 hr. In some ChIP
experiments, AML-12 cells were starved of serum and glucose for 6 hr.
Anti-pan-p63 antibody (4A4, Abcam for keratinocytes, 4A4, Santa Cruz for
AML-12) or IgG was used for immunoprecipitation. Putative p63 binding sites
were scanned within 5,000 bp upstream of the 50 UTR and intron 1 for the
consensus p53/p63 binding site (el-Deiry et al., 1992; Su et al., 2010; Yang
et al., 2006). All primers used for ChIP-PCR are listed in Table S2. ABI Step
One Plus real-time PCR and SYBR green PCR master mix (Applied
Biosystems) were used for quantitative real-time PCR.
In Vivo Adenoviral Gene Transfer
A total of 2 3 109 plaque-forming units (pfu) active rat Ad-AMPKa2
(Eton Bioscience), 1 3 109 pfu human Ad-LKB1 (Vector BioLabs), or 2 3
109 pfu human Ad-Sirt1 (Vector BioLabs) was injected through the tail
vein of TAp63/ mice. Forty-eight hours after injection, livers were collect
for western blot analysis and qRT-PCR. Metformin sensitivity was measured
after metformin injection (250 mg/kg) using mice infected with human
Ad-LKB1.
Statistics
All data are represented as mean ± SEM. Data were analyzed using one-way
ANOVA test or Student’s t test for comparison between two groups. A p value
of 0.05 was considered significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures, two tables, and Supplemental
Experimental Procedures and can be found with this article online at http://dx.
doi.org/10.1016/j.cmet.2012.09.006.
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